Value of combining biological age with assessment of individual frailty to optimize management of cancer treated with targeted therapies: model of chronic myeloid leukemia treated with tyrosine kinase inhibitors (BIO-TIMER trial).
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/ drug therapy
Protein Kinase Inhibitors
/ therapeutic use
Frailty
Aged
Prospective Studies
Molecular Targeted Therapy
Longitudinal Studies
DNA Methylation
Male
Female
Quality of Life
Adult
Precision Medicine
/ methods
Middle Aged
Aged, 80 and over
Aging
Tyrosine Kinase Inhibitors
Biological Age
Chronic myeloid leukemia
Individual Frailty
Tyrosine kinase inhibitors
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
30 May 2024
30 May 2024
Historique:
received:
26
04
2024
accepted:
22
05
2024
medline:
31
5
2024
pubmed:
31
5
2024
entrez:
30
5
2024
Statut:
epublish
Résumé
In the era of targeted therapies, the influence of aging on cancer management varies from one patient to another. Assessing individual frailty using geriatric tools has its limitations, and is not appropriate for all patients especially the youngest one. Thus, assessing the complementary value of a potential biomarker of individual aging is a promising field of investigation. The chronic myeloid leukemia model allows us to address this question with obvious advantages: longest experience in the use of tyrosine kinase inhibitors, standardization of therapeutic management and response with minimal residual disease and no effect on age-related diseases. Therefore, the aim of the BIO-TIMER study is to assess the biological age of chronic myeloid leukemia or non-malignant cells in patients treated with tyrosine kinase inhibitors and to determine its relevance, in association or not with individual frailty to optimize the personalised management of each patient. The BIO-TIMER study is a multi-center, prospective, longitudinal study aiming to evaluate the value of combining biological age determination by DNA methylation profile with individual frailty assessment to personalize the management of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Blood samples will be collected at diagnosis, 3 months and 12 months after treatment initiation. Individual frailty and quality of life will be assess at diagnosis, 6 months after treatment initiation, and then annually for 3 years. Tolerance to tyrosine kinase inhibitors will also be assessed during the 3-year follow-up. The study plans to recruit 321 patients and recruitment started in November 2023. The assessment of individual frailty should make it possible to personalize the treatment and care of patients. The BIO-TIMER study will provide new data on the role of aging in the management of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors, which could influence clinical decision-making. ClinicalTrials.gov , ID NCT06130787; registered on November 14, 2023.
Sections du résumé
BACKGROUND
BACKGROUND
In the era of targeted therapies, the influence of aging on cancer management varies from one patient to another. Assessing individual frailty using geriatric tools has its limitations, and is not appropriate for all patients especially the youngest one. Thus, assessing the complementary value of a potential biomarker of individual aging is a promising field of investigation. The chronic myeloid leukemia model allows us to address this question with obvious advantages: longest experience in the use of tyrosine kinase inhibitors, standardization of therapeutic management and response with minimal residual disease and no effect on age-related diseases. Therefore, the aim of the BIO-TIMER study is to assess the biological age of chronic myeloid leukemia or non-malignant cells in patients treated with tyrosine kinase inhibitors and to determine its relevance, in association or not with individual frailty to optimize the personalised management of each patient.
METHODS
METHODS
The BIO-TIMER study is a multi-center, prospective, longitudinal study aiming to evaluate the value of combining biological age determination by DNA methylation profile with individual frailty assessment to personalize the management of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Blood samples will be collected at diagnosis, 3 months and 12 months after treatment initiation. Individual frailty and quality of life will be assess at diagnosis, 6 months after treatment initiation, and then annually for 3 years. Tolerance to tyrosine kinase inhibitors will also be assessed during the 3-year follow-up. The study plans to recruit 321 patients and recruitment started in November 2023.
DISCUSSION
CONCLUSIONS
The assessment of individual frailty should make it possible to personalize the treatment and care of patients. The BIO-TIMER study will provide new data on the role of aging in the management of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors, which could influence clinical decision-making.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov , ID NCT06130787; registered on November 14, 2023.
Identifiants
pubmed: 38816821
doi: 10.1186/s12885-024-12415-2
pii: 10.1186/s12885-024-12415-2
doi:
Substances chimiques
Protein Kinase Inhibitors
0
Tyrosine Kinase Inhibitors
0
Banques de données
ClinicalTrials.gov
['NCT06130787']
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
661Subventions
Organisme : Fondation ARC pour la Recherche sur le Cancer
ID : ARCAGEING2022040004945
Informations de copyright
© 2024. The Author(s).
Références
Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet. 2013;381:752–62.
doi: 10.1016/S0140-6736(12)62167-9
pubmed: 23395245
Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173:489–95.
doi: 10.1503/cmaj.050051
pubmed: 16129869
pmcid: 1188185
Ness KK, Wogksch MD. Frailty and aging in cancer survivors. Transl Res. 2020;221:65–82.
doi: 10.1016/j.trsl.2020.03.013
pubmed: 32360946
pmcid: 7321876
Morley JE, Vellas B, van Abellan G, Anker SD, Bauer JM, Bernabei R, et al. Frailty Consensus: a call to action. J Am Med Dir Assoc. 2013;14:392–7.
doi: 10.1016/j.jamda.2013.03.022
pubmed: 23764209
pmcid: 4084863
Tuttle CSL, Maier AB. Towards a biological geriatric assessment. Exp Gerontol. 2018;107:102–7.
doi: 10.1016/j.exger.2017.09.017
pubmed: 28964828
Campisi J, Kapahi P, Lithgow GJ, Melov S, Newman JC, Verdin E. From discoveries in ageing research to therapeutics for healthy ageing. Nature. 2019;571:183–92.
doi: 10.1038/s41586-019-1365-2
pubmed: 31292558
pmcid: 7205183
Hannum G, Guinney J, Zhao L, Zhang L, Hughes G, Sadda S, et al. Genome-wide methylation profiles reveal quantitative views of Human Aging Rates. Mol Cell. 2013;49:359–67.
doi: 10.1016/j.molcel.2012.10.016
pubmed: 23177740
Levine ME, Lu AT, Quach A, Chen BH, Assimes TL, Bandinelli S, et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging. 2018;10:573–91.
doi: 10.18632/aging.101414
pubmed: 29676998
pmcid: 5940111
Dugué P-A, Bassett JK, Joo JE, Jung C-H, Ming Wong E, Moreno-Betancur M, et al. DNA methylation-based biological aging and cancer risk and survival: pooled analysis of seven prospective studies. Int J Cancer. 2018;142:1611–9.
doi: 10.1002/ijc.31189
pubmed: 29197076
Horvath S. DNA methylation age of human tissues and cell types. Genome Biol. 2013;14:3156.
doi: 10.1186/gb-2013-14-10-r115
Morales Berstein F, McCartney DL, Lu AT, Tsilidis KK, Bouras E, Haycock P et al. Assessing the causal role of epigenetic clocks in the development of multiple cancers: a mendelian randomization study. eLife. 11:e75374.
Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966–84.
doi: 10.1038/s41375-020-0776-2
pubmed: 32127639
pmcid: 7214240
Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM-L. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the General Population. JCO. 2016;34:2851–7.
doi: 10.1200/JCO.2015.66.2866
Lebecque B, Bourgne C, Vidal V, Berger MG. DNA methylation and intra-clonal heterogeneity: the chronic myeloid leukemia model. Cancers. 2021;13:3587.
doi: 10.3390/cancers13143587
pubmed: 34298798
pmcid: 8307727
Saugues S, Lambert C, Daguenet E, Ansah HJ, Turhan A, Huguet F, et al. Real-world therapeutic response and tyrosine kinase inhibitor discontinuation in chronic phase-chronic myeloid leukemia: data from the French observatory. Ann Hematol. 2022;101:2241–55.
doi: 10.1007/s00277-022-04955-z
pubmed: 36040480
McEwen LM, Jones MJ, Lin DTS, Edgar RD, Husquin LT, MacIsaac JL, et al. Systematic evaluation of DNA methylation age estimation with common preprocessing methods and the Infinium MethylationEPIC BeadChip array. Clin Epigenetics. 2018;10:123.
doi: 10.1186/s13148-018-0556-2
pubmed: 30326963
pmcid: 6192219
Abraham P, Courvoisier DS, Annweiler C, Lenoir C, Millien T, Dalmaz F, et al. Validation of the clinical frailty score (CFS) in French language. BMC Geriatr. 2019;19:322.
doi: 10.1186/s12877-019-1315-8
pubmed: 31752699
pmcid: 6873717
Paillaud E, Soubeyran P, Caillet P, Cudennec T, Brain E, Terret C, et al. Multidisciplinary development of the geriatric core dataset for clinical research in older patients with cancer: a French initiative with international survey. Eur J Cancer. 2018;103:61–8.
doi: 10.1016/j.ejca.2018.07.137
pubmed: 30212804
Hanlon P, Nicholl BI, Jani BD, Lee D, McQueenie R, Mair FS. Frailty and pre-frailty in middle-aged and older adults and its association with multimorbidity and mortality: a prospective analysis of 493 737 UK Biobank participants. Lancet Public Health. 2018;3:e323–32.
doi: 10.1016/S2468-2667(18)30091-4
pubmed: 29908859
pmcid: 6028743
Huan-Tze L, Yun-Ru L, Kuan-Der L, Huey-En T. Frailty in chronic myeloid leukemia: evidence from 2016–2018 Nationwide Inpatient Sample of the US. BMC Geriatr. 2023;23:334.
doi: 10.1186/s12877-023-03962-7
pubmed: 37254068
pmcid: 10228104
Cantoni N, Sommavilla R, Seitz P, Kulenkampff E, Kahn S, Lambert J-F, et al. A multicenter real-world evidence study in the Swiss treatment landscape of chronic myeloid leukemia. BMC Cancer. 2022;22:1192.
doi: 10.1186/s12885-022-10241-y
pubmed: 36402993
pmcid: 9675134
Gale CR, Marioni RE, Harris SE, Starr JM, Deary IJ. DNA methylation and the epigenetic clock in relation to physical frailty in older people: the Lothian Birth Cohort 1936. Clin Epigenetics. 2018;10:101.
doi: 10.1186/s13148-018-0538-4
pubmed: 30075802
pmcid: 6091041
Guarasci F, D’Aquila P, Montesanto A, Corsonello A, Bellizzi D, Passarino G. Individual DNA methylation Profile is correlated with age and can be targeted to modulate healthy aging and longevity. Curr Pharm Design 25:4139–49.
McCrory C, Fiorito G, Hernandez B, Polidoro S, O’Halloran AM, Hever A, et al. GrimAge outperforms other Epigenetic clocks in the prediction of age-related clinical phenotypes and all-cause mortality. J Gerontol Biol Sci Med Sci. 2020;76:741–9.
doi: 10.1093/gerona/glaa286
Verschoor CP, Lin DTS, Kobor MS, Mian O, Ma J, Pare G, et al. Epigenetic age is associated with baseline and 3-year change in frailty in the Canadian longitudinal study on aging. Clin Epigenetics. 2021;13:163.
doi: 10.1186/s13148-021-01150-1
pubmed: 34425884
pmcid: 8381580
Breitling LP, Saum K-U, Perna L, Schöttker B, Holleczek B, Brenner H. Frailty is associated with the epigenetic clock but not with telomere length in a German cohort. Clin Epigenetics. 2016;8:21.
doi: 10.1186/s13148-016-0186-5
pubmed: 26925173
pmcid: 4768341
Li X, Zhang Y, Gào X, Holleczek B, Schöttker B, Brenner H. Comparative validation of three DNA methylation algorithms of ageing and a frailty index in relation to mortality: results from the ESTHER cohort study. eBioMedicine. 2021;74.
Mak JKL, Karlsson IK, Tang B, Wang Y, Pedersen NL, Hägg S et al. Temporal Dynamics of Epigenetic Aging and Frailty from midlife to Old Age. Journals Gerontology: Ser A. 2023;:glad251.